TD Cowen Forecasts Strong Price Appreciation for NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics (NASDAQ:NEO) had its price objective boosted by research analysts at TD Cowen from $13.00 to $14.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target would suggest a potential upside of 57.48% from the company’s previous close.

Several other equities research analysts also recently issued reports on NEO. Benchmark raised shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Wednesday. Leerink Partners raised shares of NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $12.00 to $25.00 in a research note on Wednesday. Needham & Company LLC lifted their price target on shares of NeoGenomics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. William Blair reaffirmed a “market perform” rating on shares of NeoGenomics in a research note on Monday, March 16th. Finally, Piper Sandler lifted their price target on shares of NeoGenomics from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. Seven investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $13.38.

NeoGenomics Stock Down 1.4%

NeoGenomics stock traded down $0.13 during midday trading on Wednesday, hitting $8.89. 8,263,632 shares of the stock were exchanged, compared to its average volume of 2,025,261. NeoGenomics has a 1 year low of $4.72 and a 1 year high of $13.74. The firm has a market cap of $1.16 billion, a P/E ratio of -10.51 and a beta of 1.72. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.26 and a quick ratio of 3.94. The company has a 50 day moving average price of $8.50 and a two-hundred day moving average price of $10.45.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, April 28th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.01. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The firm had revenue of $186.67 million for the quarter, compared to the consensus estimate of $184.53 million. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, sell-side analysts predict that NeoGenomics will post -0.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NeoGenomics

A number of hedge funds have recently bought and sold shares of NEO. First Light Asset Management LLC boosted its holdings in shares of NeoGenomics by 45.0% in the 3rd quarter. First Light Asset Management LLC now owns 9,927,269 shares of the medical research company’s stock valued at $76,639,000 after buying an additional 3,080,837 shares during the period. Loomis Sayles & Co. L P acquired a new position in shares of NeoGenomics in the 4th quarter valued at about $19,182,000. American Capital Management Inc. boosted its holdings in shares of NeoGenomics by 120.9% in the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after buying an additional 1,283,390 shares during the period. Aberdeen Group plc boosted its holdings in shares of NeoGenomics by 127.1% in the 4th quarter. Aberdeen Group plc now owns 1,798,939 shares of the medical research company’s stock valued at $21,156,000 after buying an additional 1,006,676 shares during the period. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in shares of NeoGenomics by 69.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,218,727 shares of the medical research company’s stock valued at $26,093,000 after buying an additional 912,788 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics News Summary

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Leerink Partners upgraded NEO to “outperform” and raised its price target to $25 (from $12), signaling strong upside potential from current levels and likely attracting buy-side interest. Read More. Read More.
• Positive Sentiment: Q1 results: NeoGenomics posted $0.01 EPS (in line with consensus) and revenue of $186.67M, modestly beating estimates and showing 11.3% year‑over‑year revenue growth — a sign of continued top-line momentum. Read More.
• Neutral Sentiment: FY‑2026 revenue guidance was issued at $797M–$803M, essentially in line with consensus (~$796.6M); EPS guidance in the release was not clearly stated, leaving some forward-profitability clarity missing. Read More.
• Neutral Sentiment: Management commentary and the full Q1 earnings call transcript are available for detail on volume trends, mix, and margin drivers — useful for investors deciding if revenue growth can translate to improved profitability. Read More.
• Negative Sentiment: Market concerns about volume growth and margin pressure persist: analysts and coverage pieces flagged questions around sustainable volume expansion and the company’s negative net margin and ROE, which likely pressured the stock despite the topline beat. Read More.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.